Sanofi

Aventis Pharma S.a.

Other

Sanofi-aventis

Rhone-poulenc Rorer S.a.

Exelixis, Inc.

Sanof Aventis

Vanderbilt University

Veronique Blanc

Francis Blanche

Joel Crouzet

Denis Thibaut

Laurent Debussche

Patricia Lacroix

Valerie De Crecy-Lagard

Monique Zagorec

Nathalie Jacques

Daniel J Tavares

Michel Streuli

Chonghui Zhang

Fabienne Parker

Claudia Fromond

Jiawen Han

Xiao-Mai Zhou

Min Li

Peter U Park

Vincent Mikol

Dana T Aftab

Jutta Deckert

Anna Skaletskaya

Laura M Bartle

Marielle Chiron-Blondel

Carlos L Arteaga

Loic Vincent

Viktor Golmakher

Ariella Hanker

Celine Nicolazzi

Marielle Chiron-Blonde

Anindita Chakrabarty

Viktor S Golmakher

Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.

EPHA2 receptor antagonist antibodies

The present invention provides methods of treating cancer by administering a compound of formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with an inhibitor that targets HER2 and/or HER3. 

Combinations of kinase inhibitors for the treatment of cancer

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the A class of Eph receptors.

Methods of use for antibodies that specifically bind to the EphA2 receptor

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CD38 protein.

Anti-CD38 antibodies for the treatment of cancer

The invention concerns methods for preparing pristinamycin IIA or IIB.

Polypeptides involved in the biosynthesis of streptogramins, nucleotide sequences coding for these polypeptides and their use

The invention concerns methods for preparing pristinamycin IIB and methods for preparing modified pristinamycin IIB.

The invention concerns mutant microorganisms blocked in a step of Streptogramin biosynthesis and methods for preparing cells blocked in a step of Streptogramin biosynthesis.

Disclosed is the nucleic acid sequences for polypeptides and enzymes involved in the biosynthesis of streptogramins from Streptomyces sp. and the corresponding amino acid sequences. Also disclosed are recombinant vectors and cells as well as methods of making the polypeptides, enzymes and streptogramins using the recombinant host cells.

Polypeptides involved in the biosynthesis of streptogramins, nucleotide

Growing community of inventors

Paris, France

Veronique Blanc